Interaction of Methylene Blue with Severe Acute Respiratory Syndrome Coronavirus 2 Envelope Revealed by Molecular Modeling

被引:0
|
作者
Kovalenko, Ilya [1 ,2 ]
Kholina, Ekaterina [1 ]
Fedorov, Vladimir [1 ]
Khruschev, Sergei [1 ]
Vasyuchenko, Ekaterina [1 ]
Meerovich, Gennady [3 ,4 ]
Strakhovskaya, Marina [1 ]
机构
[1] Lomonosov Moscow State Univ, Fac Biol, Moscow 119234, Russia
[2] Pskov State Univ, Sci & Educ Math Ctr, Sofia Kovalevskaya Northwestern Ctr Math Res, Pskov 180000, Russia
[3] Russian Acad Sci, Prokhorov Gen Phys Inst, Moscow 119991, Russia
[4] Natl Res Nucl Univ MEPhI, Inst Phys & Engn Biomed, Moscow 115409, Russia
关键词
methylene blue; SARS-CoV-2; envelope; viral membrane; structural proteins; electrostatic interactions; Brownian dynamics; coarse grain modeling; PHOTODYNAMIC INACTIVATION; FORCE-FIELD; PROTEIN; PLASMA; VIRUS; DYNAMICS; THERAPY;
D O I
10.3390/ijms242115909
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Methylene blue has multiple antiviral properties against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2). The ability of methylene blue to inhibit different stages of the virus life cycle, both in light-independent and photodynamic processes, is used in clinical practice. At the same time, the molecular aspects of the interactions of methylene blue with molecular components of coronaviruses are not fully understood. Here, we use Brownian dynamics to identify methylene blue binding sites on the SARS-CoV-2 envelope. The local lipid and protein composition of the coronavirus envelope plays a crucial role in the binding of this cationic dye. Viral structures targeted by methylene blue include the S and E proteins and negatively charged lipids. We compare the obtained results with known experimental data on the antiviral effects of methylene blue to elucidate the molecular basis of its activity against coronaviruses.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Vaccines for Severe Acute Respiratory Syndrome Coronavirus 2 Infection
    Dellarocca, Mena Alrais
    US PHARMACIST, 2021, 46 (04) : 21 - 27
  • [32] Secretion of severe acute respiratory syndrome coronavirus 2 in urine
    Bronimann, Stephan
    Rebhan, Katharina
    Lemberger, Ursula
    Misrai, Vincent
    Shariat, Shahrokh F.
    Pradere, Benjamin
    CURRENT OPINION IN UROLOGY, 2020, 30 (05) : 735 - 739
  • [33] Preeclampsia treatment in severe acute respiratory syndrome coronavirus 2
    Joudi, Noor
    Henkel, Andrea
    Lock, W. Scott
    Lyell, Deirdre
    AMERICAN JOURNAL OF OBSTETRICS & GYNECOLOGY MFM, 2020, 2 (03)
  • [34] Predicting the recombination potential of severe acute respiratory syndrome coronavirus 2 and Middle East respiratory syndrome coronavirus
    Banerjee, Arinjay
    Doxey, Andrew C.
    Tremblay, Benjamin J-M
    Mansfield, Michael J.
    Subudhi, Sonu
    Hirota, Jeremy A.
    Miller, Matthew S.
    McArthur, Andrew G.
    Mubareka, Samira
    Mossman, Karen
    JOURNAL OF GENERAL VIROLOGY, 2020, 101 (12): : 1251 - 1260
  • [35] Modeling transmission dynamics of severe acute respiratory syndrome coronavirus 2 in Sao Paulo, Brazil
    da Cruz, Pedro Alexandre
    Crema-Cruz, Leandra Cristina
    Campos, Fabricio Souza
    REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL, 2021, 54 : 1 - 8
  • [36] Survival of severe acute respiratory syndrome coronavirus
    Lai, MYY
    Cheng, PKC
    Lim, WWL
    CLINICAL INFECTIOUS DISEASES, 2005, 41 (07) : E67 - E71
  • [37] The severe acute respiratory syndrome coronavirus in tears
    Tong, T
    Lai, TST
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2005, 89 (03) : 392 - 392
  • [38] Coronavirus in severe acute respiratory syndrome (SARS)
    Chan, HLY
    Tsui, SKW
    Sung, JJY
    TRENDS IN MOLECULAR MEDICINE, 2003, 9 (08) : 323 - 325
  • [39] Novel coronavirus and severe acute respiratory syndrome
    Falsey, AR
    Walsh, EE
    LANCET, 2003, 361 (9366): : 1312 - 1313
  • [40] The severe acute respiratory syndrome coronavirus in tears
    Loon, SC
    Teoh, SCB
    Oon, LLE
    Se-Thoe, SY
    Ling, AE
    Leo, YS
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2004, 88 (07) : 861 - 863